ER 145
Alternative Names: ER-000145; ER-145Latest Information Update: 09 Jan 2024
At a glance
- Originator Centre National de la Recherche Scientifique; University Paris Descartes
- Developer Ermium Therapeutics
- Class Anti-inflammatories; Small molecules
- Mechanism of Action CXCR4 receptor agonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Systemic lupus erythematosus
Most Recent Events
- 10 Nov 2023 Pharmacodynamics data from preclinical trial in Systemic lupus erythematosus presented at the ACR Convergence 2023
- 05 Jan 2023 Preclinical trials in Systemic lupus erythematosus in France (IP) before January 2023
- 10 Nov 2022 Adverse events and pharmacodynamics data from preclinical studies in Systemic lupus erythematous released by Ermium Therapeutics